Overview and Diagnostic Strategy Shifts
Celiac Disease (CD) is an immune-mediated enteropathy triggered by ingested gluten (gliadin peptides) in genetically susceptible individuals carrying HLA-DQ2 or HLA-DQ8. Historically, diagnosis strictly mandated small-bowel biopsy demonstrating villous atrophy. Modern pediatric practice, guided by the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN, 2020 update), emphasizes a standardized "no-biopsy approach" while refining criteria for histological confirmation and long-term surveillance.
The ESPGHAN Diagnostic Protocol
flowchart TD
A["Suspected Celiac Disease (Symptoms OR High-Risk Screening)"] --> B["Initial Step: Total Serum IgA + Anti-tTG IgA"]
B --> C{"Total IgA Normal for Age?"}
C -->|No: Selective IgA Deficiency| D["Test IgG-based Serology:<br/>DGP-IgG and/or anti-tTG IgG"]
D --> E["If positive: Proceed to Upper GI Endoscopy & Multiple Duodenal Biopsies"]
C -->|Yes| F{"Anti-tTG IgA Level?"}
F -->|"< 10× Upper Limit of Normal (ULN)"| G["Uncertain Serology:<br/>Proceed to Upper GI Endoscopy + ≥ 5 Biopsies"]
F -->|"≥ 10× Upper Limit of Normal (ULN)"| H["No-Biopsy Pathway:<br/>Draw SECOND independent blood sample for EMA-IgA"]
H --> I{"EMA-IgA Positive on 2nd Sample?"}
I -->|Yes| J["Celiac Disease Confirmed Without Biopsy<br/>Initiate Strict Lifelong Gluten-Free Diet (GFD)"]
I -->|No| G
1. The "No-Biopsy Approach" (ESPGHAN Criteria)
A definitive diagnosis of celiac disease can be made without upper gastrointestinal endoscopy or duodenal biopsy when all of the following conditions are met:
- High-Titer Anti-tTG IgA: Serum tissue transglutaminase IgA is $\ge 10\times$ the Upper Limit of Normal (ULN) using a validated calibration curve.
- Positive Endomysial Antibody (EMA-IgA): Endomysial IgA positivity confirmed on a second, independently drawn blood sample (rules out laboratory labeling errors or transient false positives).
- Symptom Status Irrelevant: The 2020 ESPGHAN update demonstrated equal diagnostic accuracy ($>99\%$ positive predictive value) in both symptomatic children and asymptomatic screened cohorts (e.g., Type 1 Diabetes, Down syndrome, first-degree relatives).
- Abandonment of Mandatory HLA Typing: HLA-DQ2 and HLA-DQ8 genetic testing is no longer required for confirming the no-biopsy diagnosis. Because 30–40% of the healthy general population carries HLA-DQ2/DQ8, a positive test has poor positive predictive value; its clinical utility is strictly limited to its negative predictive value ($>99\%$) to rule out CD.
When Upper GI Endoscopy and Biopsy Remain Mandatory
Endoscopy with biopsy is mandatory in:
- Low-Titer Positivity: Anti-tTG $\text{IgA} < 10\times\text{ ULN}$.
- Discordant Serology: High-tTG IgA with a negative second-sample EMA-IgA.
- Selective IgA Deficiency: Serum $\text{IgA} < 0.2\text{ g/L}$ with positive DGP-IgG or tTG-IgG.
- Diagnostic Uncertainty: Persistent gastrointestinal symptoms or failure to thrive despite borderline serologies.
Biopsy Protocol and Histopathology
- Sampling Density: A minimum of 5 biopsies must be obtained:
- At least 4 biopsies from the distal duodenum (second and third parts).
- At least 1 to 2 biopsies from the duodenal bulb (patchy mucosal lesions may be confined solely to the bulb).
- Histopathology (Modified Marsh-Oberhuber Classification):
- Marsh 0: Pre-infiltrative (normal mucosal architecture).
- Marsh 1: Infiltrative ($>25\text{ Intraepithelial Lymphocytes [IELs] per 100 enterocytes}$).
- Marsh 2: Hyperplastic (increased IELs + crypt hyperplasia).
- Marsh 3: Destructive (villous atrophy: 3a = partial, 3b = subtotal, 3c = total villous blunting). A Marsh $\ge 2$ or 3 lesion is required for histological diagnosis.
Dietary Management and Objective Adherence Monitoring
1. Gluten-Free Diet (GFD) Standards
- Strict Lifelong Elimination: Avoidance of wheat, rye, and barley. Pure, uncontaminated oats are tolerated by $>95\%$ of pediatric patients but should only be introduced after symptom and serological normalization.
- Gluten Threshold: International Codex Alimentarius defines "gluten-free" as $< 20\text{ parts per million (ppm)}$ ($< 20\text{ mg/kg}$ of food product).
2. Follow-Up Schedule and Objective Monitoring Tools
- Clinical Surveillance: Follow-up at 3 to 6 months post-GFD initiation, then annually. Monitor linear growth, weight-for-age, pubertal progress, and screen for micronutrient deficiencies (iron, ferritin, vitamin D, calcium, folate, zinc).
- Serological Normalization: Anti-tTG IgA titers typically drop by $>50\%$ within 3 months and normalize within 12 months. Persistent elevation beyond 12–24 months indicates continued occult gluten ingestion.
- Gluten Immunogenic Peptides (GIP): Novel objective point-of-care lateral flow or ELISA assays detect resistant gliadin peptide fragments directly in urine or stool. GIP detection identifies accidental or intentional gluten exposure occurring within the preceding 24 to 48 hours, overcoming the limitations of dietary recall interviews.
Emerging Non-Dietary Therapeutics
While a strict GFD remains the primary therapy, multiple adjuncts are in clinical trials for refractory celiac disease or accidental gluten exposure:
- Tissue Transglutaminase Inhibitors (e.g., ZED1227): Specific oral small-molecule inhibitor that blocks mucosal TG2 activity, preventing the deamidation of gliadin peptides and subsequent immune activation. Phase 2 trials show marked protection against gluten challenge-induced mucosal damage.
- Oral Enzymatic Therapies (Latiglutenase / ALV003): Orally administered combination endopeptidases that rapidly digest gluten fragments in the stomach before they reach the duodenal lumen.
- Immune-Tolerizing Vaccines & Monoclonal Antibodies: Nanoparticles encapsulating gliadin peptides (e.g., TAK-101) designed to induce antigen-specific immune tolerance; Anti-IL-15 monoclonal antibodies (e.g., PRV-015) targeting the intraepithelial lymphocyte survival pathway in refractory celiac disease.